PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 14149946

INITIAL EXPERIENCE WITH THROMBOTEST.

A L MILLER·G FARRER-BROWN·J PETHER
View original source ↗Export metadata ↓

Abstract

The initial experience of using Thrombotest instead of Quick's one-stage prothrombin time to control anticoagulant therapy is described.Patients well controlled by the Quick test are often found to be over-anticoagulated by Thrombotest standards, so the introduction of Thrombotest has led to widespread reductions in dosage. No improvement in stability of control has been noted. The main advantages of Thrombotest seem to be its technical simplicity and the comparability of results obtained in different laboratories.

Explore related subjects

AnticoagulantsBlood CoagulationBlood Coagulation TestsHumansPhenindioneProthrombin TimeANTICOAGULANTSBLOOD COAGULATION TESTSPHENINDIONEJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A L MILLER, G FARRER-BROWN, J PETHER. 1964. INITIAL EXPERIENCE WITH THROMBOTEST.. https://doi.org/10.1136/jcp.17.2.182

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2004

Activated protein C variants with normal cytoprotective but reduced anticoagulant activity.

Recombinant activated protein C (APC), a well-defined anticoagulant enzyme, reduced mortality in severe sepsis patients in a phase 3 trial. However, 2 potent anticoagulants, antithrombin III and recombinant tissue factor pathway inhibitor, failed to do so, implying the physiologic relevance of APC's less well-defined anti-inflammatory and antiapoptotic activities. Recombinant APC therapy conveys an increased risk of serious bleeding complications due to APC anticoagulant activity. To generate recombinant APC variants with reduced risk of bleeding due to reduced anticoagulant activity, we dissected APC's anticoagulant activity from its cytoprotective activity by site-directed mutagenesis. Using staurosporine-induced endothelial cell apoptosis assays, we show here that Ala mutations (RR229/230AA and KKK191_ 193AAA) in 2 APC surface loops that severely reduce anticoagulant activity result in 2 APC variants that retain normal antiapoptotic activity that requires protease activated receptor-1 and endothelial cell protein C receptor. Thus, it is possible to reduce anticoagulant activity while preserving antiapoptotic activity of recombinant APC variants. We suggest that therapeutic use of such APC variants may reduce serious bleeding risks while providing the beneficial effects of APC acting directly on cells.

Anticoagulants↗